# Alan Dal Pra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3184620/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 77 papers | 2,565 citations | 361413 20 h-index | 206112 48 g-index |
| 77 all docs | 77 docs citations | 77 times ranked | 4929 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Genomic hallmarks of localized, non-indolent prostate cancer. Nature, 2017, 541, 359-364. | 27.8 | 462 |
| 2 | Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics, 2015, 47, 736-745. | 21.4 | 395 |
| 3 | Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncology, The, 2014, 15, 1521-1532. | 10.7 | 291 |
| 4 | Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response. Clinical Cancer Research, 2013, 19, 6741-6750. | 7.0 | 268 |
| 5 | A Prostate Cancer â€œ Nimbosus â€• Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology, 2017, 72, 665-674. | 1.9 | 142 |
| 6 | A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. European Urology, 2021, 79, 374-383. | 1.9 | 93 |
| 7 | Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. Journal of Translational Medicine, 2018, 16, 223. | 4.4 | 60 |
| 8 | Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 982-995. | 0.8 | 56 |
| 9 | Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. Radiation Oncology, 2018, 13, 216. | 2.7 | 46 |
| 10 | Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist. British Journal of Radiology, 2016, 89, 20160217. | 2.2 | 43 |
| 11 | Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nature Reviews Urology, 2015, 12, 193-204. | 3.8 | 41 |
| 12 | Objective consensus from decision trees. Radiation Oncology, 2014, 9, 270. | 2.7 | 40 |
| 13 | TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. Clinical Cancer Research, 2013, 19, 5202-5209. | 7.0 | 39 |
| 14 | Segmentation of prostate and prostate zones using deep learning. Strahlentherapie Und Onkologie, 2020, 196, 932-942. | 2.0 | 36 |
| 15 | Intratumoral Hypoxia as the Genesis of Genetic Instability and Clinical Prognosis in Prostate Cancer. Advances in Experimental Medicine and Biology, 2014, 772, 189-204. | 1.6 | 28 |
| 16 | Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy. Translational Andrology and Urology, 2018, 7, 445-458. | 1.4 | 26 |
| 17 | Stereotactic Fractionated Radiotherapy in the Treatment of Juxtapapillary Choroidal Melanoma: The McGill University Experience. International Journal of Radiation Oncology Biology Physics, 2011, 81, e455-e462. | 0.8 | 24 |
| 18 | The role of radiomics in prostate cancer radiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 900-912. | 2.0 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | T1â€“2 glottic cancer treated with radiotherapy and/or surgery. Strahlentherapie Und Onkologie, 2017, 193, 995-1004. | 2.0 | 23 |
| 20 | Prostate cancer radiation therapy: A physicianâ€™s perspective. Physica Medica, 2016, 32, 438-445. | 0.7 | 22 |
| 21 | Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: Rationale, complications, toxicity rates, and oncological outcomes â€“ A systematic review. Radiotherapy and Oncology, 2016, 119, 185-193. | 0.6 | 21 |
| 22 | Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Frontiers in Oncology, 2016, 6, 24. | 2.8 | 20 |
| 23 | Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature. Cancer Treatment Reviews, 2016, 46, 35-41. | 7.7 | 20 |
| 24 | Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Radiotherapy and Oncology, 2018, 126, 257-262. | 0.6 | 19 |
| 25 | Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland. Strahlentherapie Und Onkologie, 2015, 191, 778-786. | 2.0 | 18 |
| 26 | Disease Control With Delayed Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy. Frontiers in Oncology, 2019, 9, 12. | 2.8 | 17 |
| 27 | The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment. Critical Reviews in Oncology/Hematology, 2021, 168, 103497. | 4.4 | 17 |
| 28 | An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System forÂDefining External Beam Radiation Therapy Boost Volumes. International Journal of Radiation Oncology Biology Physics, 2018, 102, 821-829. | 0.8 | 16 |
| 29 | Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer. British Journal of Radiology, 2020, 93, 20200028. | 2.2 | 16 |
| 30 | Radiation therapy and androgen deprivation in the management of high risk prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 161-179. | 1.5 | 15 |
| 31 | Urethral strictures after radiation therapy for prostate cancer. Investigative and Clinical Urology, 2016, 57, 309. | 2.0 | 15 |
| 32 | Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. Radiotherapy and Oncology, 2011, 101, 486-489. | 0.6 | 14 |
| 33 | Outcomes in Advanced Head and Neck Cancer Treated with Up-front Neck Dissection prior to (Chemo)Radiotherapy. Otolaryngology - Head and Neck Surgery, 2016, 154, 300-308. | 1.9 | 14 |
| 34 | Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 9-16. | 2.0 | 14 |
| 35 | Impacts of postâ€radiotherapy lymphocyte count on progressionâ€free and overall survival in patients with stage III lung cancer. Thoracic Cancer, 2020, 11, 3139-3144. | 1.9 | 14 |
| 36 | Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiation Oncology, 2019, 14, 177. | 2.7 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Repeatability of CBCT radiomic features and their correlation with CT radiomic features for prostate cancer. Medical Physics, 2021, 48, 2386-2399. | 3.0 | 13 |
| 38 | Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database. Radiation Oncology, 2016, 11, 48. | 2.7 | 12 |
| 39 | Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. European Urology Focus, 2015, 1, 173-184. | 3.1 | 11 |
| 40 | Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. Physica Medica, 2020, 77, 154-159. | 0.7 | 11 |
| 41 | Shifting the Curtainâ€"Can We Make Sense of the Whole Pelvis Controversy?. International Journal of Radiation Oncology Biology Physics, 2020, 106, 534-536. | 0.8 | 9 |
| 42 | Definitive intensity modulated radiotherapy in locally advanced hypopharygeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure. Radiation Oncology, 2015, 10, 20. | 2.7 | 8 |
| 43 | Assessment of Knowledge-Based Planning for Prostate Intensity Modulated Proton Therapy. International Journal of Particle Therapy, 2021, 8, 62-72. | 1.8 | 8 |
| 44 | Clinicogenomic characterization of prostate cancer liver metastases. Prostate Cancer and Prostatic Diseases, 2022, 25, 366-369. | 3.9 | 7 |
| 45 | Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 114, 718-724. | 0.8 | 6 |
| 46 | Contemporary role of postoperative radiotherapy for prostate cancer. Translational Andrology and Urology, 2018, 7, 399-413. | 1.4 | 5 |
| 47 | Radiation-Induced Lymphopenia Beyond the COVID-19 Pandemic. Frontiers in Oncology, 2020, 10, 617302. | 2.8 | 5 |
| 48 | Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. Journal of Urology, 2021, 205, 1344-1351. | 0.4 | 5 |
| 49 | Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 80-91. | 0.8 | 5 |
| 50 | | | |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Primary tumor volume delineation in head and neck cancer: missing the tip of the iceberg?. Radiation Oncology, 2017, 12, 102. | 2.7 | 3 |
| 56 | Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).. Journal of Clinical Oncology, 2021, 39, 5010-5010. | 1.6 | 3 |
| 57 | Does transperitoneal minimally invasive radical prostatectomy increase the amount of small bowel receiving salvage radiation?. Canadian Urological Association Journal, 2013, 7, 444. | 0.6 | 2 |
| 58 | Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genetics, 2021, 258-259, 61-68. | 0.4 | 2 |
| 59 | Can texture analysis of pre-immunotherapy CT imaging predict clinical outcomes for patients with advanced NSCLC treated with Nivolumab?. Journal of Clinical Oncology, 2019, 37, e20720-e20720. | 1.6 | 2 |
| 60 | Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?. Journal of Clinical Oncology, 2020, 38, 9579-9579. | 1.6 | 2 |
| 61 | Liver Failure After Abdominal Irradiation: Identifying the Right Suspects. Journal of Clinical Oncology, 2016, 34, e80-e83. | 1.6 | 1 |
| 62 | Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910â€“7. European Urology, 2018, 73, e34-e35. | 1.9 | 1 |
| 63 | Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and Selection. European Urology, 2019, 75, 419-422. | 1.9 | 1 |
| 64 | SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy.. Journal of Clinical Oncology, 2018, 36, TPS157-TPS157. | 1.6 | 1 |
| 65 | Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50â€“7 Re: Ronald C. Chen. Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy. Eur Urol 2016;69:58â€“9. European Urology, 2016, 69, e74-e75. | 1.9 | 0 |
| 66 | Editorial: Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer. Frontiers in Oncology, 2017, 7, 275. | 2.8 | 0 |
| 67 | Re: GaÃ«tan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol 2019;76:265â€“7. European Urology, 2019, 76, e148-e149. | 1.9 | 0 |
| 68 | Re: Carlo A. Bravi, Nicoal Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Eur Urol 2020;78:661â€“9. European Urology, 2020, 78, e221-e222. | 1.9 | 0 |
| 69 | TMPRSS2-ERG status and biochemical recurrence following radiotherapy for intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 11-11. | 1.6 | 0 |
| 70 | Association of tumor hypoxia with lower survival after radiotherapy for muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2012, 30, 292-292. | 1.6 | 0 |
| 71 | Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 117-117. | 1.6 | 0 |
| 72 | Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).. Journal of Clinical Oncology, 2016, 34, 96-96. | 1.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.. Journal of Clinical Oncology, 2016, 34, 49-49. | 1.6 | 0 |
| 74 | Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5051-5051. | 1.6 | 0 |
| 75 | Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture. , 2016, , . | | 0 |
| 76 | Abstract A28: Mutational landscape of TP53 in localized prostate cancer. , 2017, , . | | 0 |
| 77 | Using hormone therapy with salvage radiotherapy according to presalvage PSA levels. Nature Reviews Urology, 2020, 17, 489-490. | 3.8 | 0 |